Page 4 - T Dxd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from T dxd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In T Dxd Today - Breaking & Trending Today

Trastuzumab Deruxtecan May Represent Potential Option for HER2-Expressing Solid Tumors

Funda Meric-Bernstam, MD, discusses the design of the DESTINY-PanTumor02 trial, details the antitumor activity and safety of T-DXd in HER2-expressing solid tumors, and shares additional analyses that will be coming down the pike. ....

United States , Nellieb Connally , Institute For Personalized Cancer Therapy , Phasei Program , Department Of Investigational Cancer Therapeutics , University Of Texas Md Anderson Cancer Center , Funda Meric Bernstam , Investigational Cancer Therapeutics , Personalized Cancer Therapy , Breast Cancer , Cancer Center , Neoadjuvant Her2 , Fam Trastuzumab Deruxtecan Nxki , T Dxd , Destiny Pantumor02 Trial ,

Dr Reckamp on the Landscape of Current and Emerging ADCs in NSCLC

Karen L. Reckamp, MD, MS, discusses current and emerging antibody-drug conjugates in lung cancer in addition to highlighting the development of patritumab deruxtecan and telisotuzumab vedotin.
....

Karenl Reckamp , Sinai Medical Center , Lung Institute , Clinical Research , Division Of Medical Oncology , Sinai Samuel Oschin Comprehensive Cancer Institute , Medical Oncology , Cedars Sinai Medical Center , Lung Cancer , T Dxd , Her3 Dxd , Elisotuzumab Vedotin , Antibody Drug Conjugates ,

Real-World Patient Characteristics and Treatment Patterns Associated With Tucatinib Therapy in Patients With HER2+ Metastatic Breast Cancer

Jane Lowe Meisel, MD, presents data from a retrospective study investigating patient characteristics, treatment patterns, and clinical outcomes for tucatinib-based treatment in the real-world setting both overall and following fam-trastuzumab deruxtecan (T-DXd). ....

Jane Lowe Meisel , Real World Patient Characteristics , Patients With , Metastatic Breast , Lowe Meisel , Her2 Metastatic Breast Cancer , Tucatinib Based Treatment , Fam Trastuzumab Deruxtecan , T Dxd , Her2 Targeted Therapies , Active Brain Metasases ,

Remaining Unmet Needs in the Third-Line and Lessons from HER2CLIMB

Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine. ....

Sara Hurvitz , Breast Cancer , Her2 Breast Cancer , Her2 Positive Breast Cancer , Metastatic Breast Cancer , Third Line Therapy , Brain Metastases , Cns Metastases , Cumulative Toxicity , Cardiac Toxicity , Tyrosine Kinase Inhibitors , Topoisomerase Inhibitors , Antibody Drug Conjugates , Trastuzumab Deruxtecan , Trastuzumab Emtansine , T Dm1 , T Dxd , Cns Progression ,

Use of ADCs in the Second-Line Treatment of HER2+ mBC

Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases. ....

Sara Hurvitz , Melindal Telli , Heather Mcarthur , Breast Cancer , Her2 Breast Cancer , Her2 Positive Breast Cancer , Metastatic Breast Cancer , Second Line Therapy , Trastuzumab Deruxtecan , Trastuzumab Emtansine , T Dm1 , T Dxd , Destiny Breast03 , Db 03 , Interstitial Lung Disease , Blood Brain Barrier , Brain Metastases , Tuxedo 1 ,